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Summary 
The CD34 antigen defines a subset of hematopoietic progenitor cells with self-renewal capacity 
and the ability to reconstitute hematopoiesis in irradiated primates and marrow-ablated humans, 
but its function remains unknown.  The c-myb protooncogene plays a fundamental role in he- 
matopoiesis, most likely via its transcriptional regulator function. We report that c-myb protein 
transactivates  the CD34 promoter via specific interaction  with multiple Myb binding  sites in 
the 5' flanking region  of the gene and induces expression of the endogenous  CD34 mtLNA 
in rodent fibroblasts.  Also, constitutive expression of c-myb in CD34-negative human glioblastoma 
cells induces expression of CD34 mRNA and synthesis of the surface membrane antigen. These 
data directly demonstrate  that  c-myb regulates  the expression of the hematopoietic  stem cell 
antigen CD34 and raise the possibility that c-myb regulates hematopoiesis inducing a cascade 
of differentiation-related  events. 
T 
he CD34 surface antigen is a highly glycosylated trans- 
membrane protein expressed on hematopoietic stem cells 
and  lineage-specific  progenitor  cells,  on  a  subset  of bone 
marrow stromal cells and on small vessel endothelium of a 
variety of tissues (1-4). About 1-4% of normal bone marrow 
cells and ",,30%  of blasts from acute leukemia patients  ex- 
press CD34 (1, 2, 5). To date, CD34 remains the only well- 
defined human  stem cell marker.  CD34-positive cells  have 
self-renewal capacity and ability to reconstitute hematopoiesis 
in sublethally irradiated primates and marrow-ablated humans 
(6, 7). The function of CD34 is not yet known,  although 
this protein has been proposed to play a role in hematopoietic 
cell adhesion to stromal cells, perhaps facilitating the interac- 
tion with locally released growth factors, and to directly func- 
tion  as a signal  transducer  (3, 4,  8). 
The mechanisms regulating CD34 expression in hemato- 
poietic cells are not well understood,  although there is evi- 
dence of transcriptional and posttranscriptional regulation of 
CD34 expression (9, 10). In light of putative Myb binding 
sites present in the 5' flanking region of the CD34 gene (9, 
11), and the fundamental role of c-myb in hematopoietic cell 
proliferation  and/or differentiation  (12-15), most likely through 
the transcription regulator function of Myb proteins (16-19), 
we investigated the possibility that c-myb is directly involved 
in transcriptional  regulation of CD34 gene, possibly by in- 
ducing expression of its mRNA and synthesis of the surface 
membrane protein in nonexpressing  cells. 
Materials  and Methods 
Gel Retardation Assay.  HB101  cells containing the parental pFlag 
(IBI, New Haven, CT) expression vector only or HB101 cells con- 
taining the pc-Myb Flag vector (20) were incubated for 4 h in the 
presence of 1.5 mM isopropyl/~-D-thiogalactopyranoside  (IPTG) 
to an OD 600 of 0.500. Myb expression was determined in bac- 
terial lysates by Western blot using an anti-Myb-specific antibody 
(Upstate  Biotechnology  Incorporated  [UBI], Lake Placid, NY). 
32p-labeled double-stranded probes were synthesized by PCR and 
corresponded to three different segments of the human CD34 5' 
flanking region from  -294 to  -115;  -132 to 54, and 67 to 234, 
based on the published sequence (9, 11). Gel retardation assays were 
performed as described (20). 
Transient Chloramt~henicol  Acetyl-Transferase  (CAT) Analysis.  Con- 
structs in which different CD34 promoter regions drive the bac- 
terial CAT gene were prepared by PCR amplification of human 
placental genomic DNA and by cloning  the different fragments 
of the CD34 5' flanking region first into  the pCRII vector (In- 
vitrogen Corp., San Diego, CA) or directly into the pUCCAT vector 
(Promega Corp., Madison, WI). CD34 SM-CAT and CD34 LM- 
CAT contain identical nucleotide substitutions in the Myb consen- 
sus sequence, from nucleotide 75 to 78 and 92 to 95 (CAAC to 
TGGC and GTTA to GCCC, respectively), of the published se- 
quence of the human CD34 gene (9, 11). TK-ts13 hamster fibro- 
blasts were transfected, using the calcium-phosphate precipitation 
method (21), with 1 #g of CAT reporter plasmid with or without 
5 #g of effector plasmid (pMbl-dhfr,  named pSV myb, containing 
the human c-myb cDNA driven by SV40 early promoter) plus 1 
/zg of a plasmid containing the bacterial fl-galactosidase gene driven 
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fection efficiency.  Cells were harvested  48 h after transfection. Pro- 
teins were extracted by freeze-thawing and normalized for trans- 
fection efficiency  using the 3-galactosidase assay, as suggested by 
the manufacturer (Promega). Cellular lysates  were incubated with 
[14C]chloramphenicol and acetyl-CoA for 1 h at 37~  Transacti- 
vation of the reporter constructs was assayed by measuring the 
amount of acetylated [14C]chloramphenicol  by thin-layer chroma- 
tography followed by autoradiography and scintillation counting. 
Detection of c-myb Protein in  Transfected Cells.  Levels  of c-myb 
protein were determined in total cell extracts from 6  x  10  6 trans- 
fected TK-ts13 hamster fibroblasts and human glioblastoma T98G 
cells by Western blot analysis  with a monoclonal anti-mouse c-myb 
antibody (UBI) and then with a peroxidase  labeled  sheep anti-mouse 
Ig antibody (Amersham Corp.,  Arlington  Heights, IL). Bound 
antibodies were revealed with the Enhance Chemiluminescence 
Detection System (ECL; Amersham Corp.). 
Expression of CD34 mRNA in Transfected Cells.  TKots13  cells 
were transfected with no plasmid, 5 #g of pSV 3-gal containing 
bacterial 3-galactosidase  DNA under the control of the SV40 early 
promoter or 5/xg of pSVmyb. RNA was extracted as described 
(22) 24, 36, or 48 h after transfection. Using 0.7/~g of total RNA 
and 40 cycles  CD34 mRNA was amplified  by reverse transcriptase 
(RT)-PCR, as described (23), with a pair of synthetic primers cor- 
responding to nucleotides from 461 to 482 (5' primer) and from 
246 to 267 (3' primer) of the published routine CD34 cDNA se- 
quence (24). Amplified  DNA was subjected  to electrophoresis,  trans- 
ferred to Zetabind nylon filters (Cuno, Inc., Meriden, CT) and de- 
tected by Southern hybridization with a y-[32p]ATP end-labeled 
oligoprobe corresponding to nucleotides 366 to 395 (24). In TK- 
tsD cells constitutively  expressing  c-myb, CD34 mR.NA levels  were 
also measured  by RT-PCR using 0.7/zg of total RNA and 40 cycles. 
In the different T98G cell lines CD34 mRNA levels  were also de- 
termined by RT-PCR. Primers used correspond to nucleotides 957 
to 982 (5' primer) and 1165 to 1190 (3' primer); the oligoprobe 
includes nucleotides 1109 to 1134, of the published human cDNA 
sequence (25). Amplification products were run on  1% agarose 
gel, blotted  and probed with the 32p end-labeled oligoprobe. 
CelISu~ace CD34 Expression.  Exponentially  growing cells were 
harvested and incubated (30 min on ice in PBS containing 0.1% 
gelatin, 0.01% sodium azide, 5  % fetal calf serum) with antibodies 
to CD34  (mouse IgG1 anti-HPCA1; Becton Dickinson & Co., 
Mountain View, CA), 32-microglobulin (BBM1) as positive con- 
trols, or CD16 (3G8, irrelevant IgG1), as negative controls. Cells 
were washed and incubated (30 min on ice) with FITC-conjugated 
goat anti-mouse  Ig F(ab')2. Cells were washed and analyzed by 
flow-cytometry on a EPICS Profile Analyzer (Coulter Corp., Hia- 
leah, FL). 
Results 
c-myb Protein Interacts with the 5' Flanking Region of  the CD34 
Gene.  To determine whether Myb interacts with putative 
Myb binding sites in the 5' flanking region of the CD34 gene, 
gel retardation assays were performed with bacterial lysates 
containing or not containing Myb protein, and probed with 
different 32p-labeled DNA fragments of the CD34 5' flank- 
ing region (Fig.  1).  One retarded complex was detected in 
the lysate containing Myb protein (Fig.  1,  lanes 2,  5,  and 
8), but none in the lysate that lacked Myb protein (Fig.  1, 
lanes 3, 6, 9, and 12). No binding was detected when a probe 
with a 3-base substitution in each of the two potential Myb 
Figure  1.  Myb protein binding to CD34 5' flanking  region. Lanes 1, 
4, 7, and I0, free probe only; lanes 3, 6, 9, and 12, probe plus 1/xg of 
parental bacterial  lysate;  lanes 2, 5, 8, and 11, probe plus 1 #g of bacterial 
lysate  containing  the human  c-myb  protein. The probe used  in lanes 10-12 
contains three nucleotide  substitutions  in both Myb binding sites. The 
different regions of the CD34 promoter used as probe are indicated  on 
the top. 
consensus sequences was used (Fig. 1, lane tt), demonstrating 
the specificity  of the interactions. 
CD34 Promoter  Activity Is 7~ansactivated by c-myh  To deter- 
mine whether c-myb transactivates  the CD34 5' flanking re- 
gion, constructs in which different fragments of the CD34 
promoter drive bacterial CAT gene expression were prepared 
by cloning the segments corresponding to nucleotides -666 
to 234 (CD34 L-CAT),  -132 to 234 (CD34 M-CAT), and 
31 to 187 (CD34 S-CAT)  (9,  11) into the pUCCAT vector 
(Fig.  2 A), and transfected into wild-type TK-ts13 Syrian 
hamster fibroblasts or in cells constitutively expressing c-myb 
(SV-mybTK-ts13).  TK-ts13 cells were transfected at  a 5:1 
effector-to-reporter  ratio with plasmid pMbm-dhfr. This plas- 
mid, which contains the human c-myb cDNA under the con- 
trol of the SV40 early promoter and enhancer linked to the 
dehydrofolate  reductase coding sequence for methotrexate se- 
lection (11) and the described above reporter plasmids,  were 
used in the experiments. Levels of CAT activity were assayed 
48 h later (Fig. 2 B). c-myb induced 8-,  10-, and 14-fold in- 
creases, respectively, in CAT expression driven by the CD34 
L-CAT (Fig. 2 B, lane 3), CD34 M-CAT (Fig. 2 B, lane 5), 
and CD34 S-CAT (Fig. 2 B, lane 7) CD34 5' flanking region 
segments. Transactivation was abolished when mutations were 
introduced in the Myb binding sites of the CD34  S-CAT 
reporter vector (CD34  SM-CAT;  Fig.  2 B,  lane 9). 
To determine whether the Myb binding sites not included 
in the segment corresponding to CD34 S-CAT (nucleotides 
31 to 187) are also involved in CD34 5' flanking region trans- 
activation, TK-ts13 and SVmybTK-ts13 cells were transfected 
with CD34 LM-CAT containing the 900-bp fragment of the 
CD34 5' flanking region with mutations in the two most prox- 
imal Myb binding sites (9, 11). Transactivation was unaffected 
(Fig. 2 B, lane 4), compared with the wild-type L-CAT con- 
struct (Fig. 2 C, bar 2), indicating that the more distal Myb 
consensus sequences are also functional binding sites. CAT 
assays were also performed using TK-ts13 or SVmybTK-ts13 
cells transfected with CD34 L-CAT and CD34 LM-CAT in 
the presence of an excess (100:1, molar ratio) of a 36-bp frag- 
ment of the CD34 5' flanking region (nucleotides 31 to 67) 
containing two wild-type or two mutated Myb binding sites. 
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with pSVCAT in the presence or absence of an excess (100:1 
molar ratio)  of competitor  (not  shown). 
CD34 Expression Is Regulated by c-myt~  To test the predic- 
tion, from the above results, that c-myb may upregulate CD34 
expression,  RT-PCR  analysis of CD34  mRNA  expression 
was performed in TK-ts13 cells 24, 36, and 48 h after trans- 
fection with pSVmyb. CD34 mRNA was detectable only in 
c-myb-expressing cells (Fig. 3 A, lanes 3-5), but not in mock- 
transfected TK-ts13 cells (Fig. 3 A,  lane 1), or in TK-ts13 
cells transfected with the pSV3-gat plasmid (Fig. 3 A, lane 
2)  used as controls.  In addition,  CD34  mRNA  expression 
was detected in SVmyb TK-ts13 cells constitutively expressing 
c-myb protein  (Fig.  3 B,  right,  lane 2). 
Antibodies  are available for detection of human,  but not 
rodent CD34 proteins; therefore, to prove that induced CD34 
mRNA expression results in synthesis and expression of the 
encoded protein,  human  glioblastoma  T98G cells  (nonex- 
pressing  c-myb)  were transfected with  a c-myb  cDNA  and 
assayed for Myb protein and CD34 expression. Western blot 
analysis revealed the presence of a 75-kD protein corresponding 
to c-myb, in SVmyb T98G cells (Fig. 4 A, lane 2), in SVmybM 
T98G cells selected with increasing concentrations of metho- 
trexate (final concentration 22 #M) to induce amplification 
Figure  2.  c-myb  transactivation  of CD34 5' flanking region in Tk-ts13 
hamster fibroblasts. (A) Constructs in which different CD34 promoter 
regions drive the bacterial  CAT gene. (B) Autoradiograms  of CAT activity 
in lysates of  TK-ts13 transfected  with the negative  control puCCAT (lane 
1), CD34 DCAT (lane 2), CD34 M-CAT (lane 4), CD34 S-CAT (lane 
6), CD34 SM-CAT (lane 8), or cotransfected  with pSV-myb  (lanes 3, 5, 
7, and 9, respectively).  (C') Scintillation  countings of acetylated  [14C]chlor- 
amphenicol  in lysates of: TK-ts13 (lane I), and SVmyb-TK-ts13  cells (lane 
2) transfected  with CD34 I~CAT; TK-ts13 (lane 3) and SV-Myb TK-ts13 
cells (lane  4) transfected  with CD34 LM-CAT,  TK-ts13  (lane  5), and SVmyb 
TK-ts13 cells (lane  6) transfected  with CD34 L-CAT  plus a synthetic com- 
petitor containing two wild-type Myb binding sites; TK-ts13 (lane 7) and 
SVmyb TK-ts13  cells (lane  8) transfected  with CD34 LM-CAT  plus a syn- 
thetic competitor containing two wild-type Myb binding sites; TK-ts13 
(lane 9) and SVmyb  TK-ts13  cells (lane 10) transfected  with CD34 L-CAT 
plus a synthetic competitor containing two mutated Myb binding sites; 
and TK-ts13 (lane 11) and SVmyb  TK-ts13  cells (lane 12) transfected  with 
CD34 LM-CAT  plus a synthetic competitor containing two mutated Myb 
binding sites. 
Transactivation of CD34 L-CAT and  CD34  LM-CAT was 
abolished by the wild-type competitor (Fig. 2 C, bars 6 and 
8) but was  unaffected by the mutated  oligomer (Fig.  2  C, 
bars 10 and 12), further demonstrating that the transactivation 
of the CD34 promoter depends directly on c-rnyb expression 
and interaction with Myb binding sites. The 36-bp competitor 
containing  two  Myb binding  sites  was  not  toxic,  as  levels 
of CAT  activity were identical in TK-ts13 cells transfected 
Figure 3.  CD34 mRNA levels  in TK-ts13 cells transfected  with pSV- 
myb. (A) Expression  of CD34 mRNA in transiently transfected  TK-ts13 
cells. (Lane 1) cells transfected  with no plasmid; (lane 2) cells transfected 
with 5/zg ofpSV 3-gal; (lanes  3-5) cells  transfected  with 5 #g of  pSVmyb. 
KNA was extracted  as described  (22) 48 h after transfection  except  in lanes 
3 and 4 (RNA extracted 24 and 36 h after transfection, respectively).  To 
exclude amplification  from genomic DNA, RT-PCR reactions  were done 
in the absence  of reverse  transcriptase  (-). In controls, reactions  were also 
performed in the absence of RNA. Endogenous ~-actin mRNA levels 
were also measured to ensure that a similar amount of RNA was analyzed 
for CD34 mP,  NA expression. (B) Expression of CD34 mRNA in TK- 
ts13 cells constitutively expressing c-myb. (Left) levels of c-myb protein 
determined  by Western  blot analysis. (Lane  1) untransfected  TK-ts13  cells; 
(lane 2) SVmybTK-ts3  cells; (lane 3) control HL-60 cells. (Right) CD34 
mRNA levels determined by RT-PCR in untransfected TK-ts13 (lane 1) 
and in SV-myb TK-ts13 cells (lane 2) in the presence (+) or absence (-) 
of reverse  transcriptase; (lane  3) P,T-PCR reaction in the absence  of RNA 
in the reaction mixture. 
1025  Melotti et al.  Brief Definitive Report Figure 4.  CD34 mRNA levels  in T98G human glioblastoma cells  con- 
stitutively expressing c-myb. (.4) Levels  of c-myb protein were determined 
by Western blot analysis in untransfected T98G cells (lane I), in SV-myb- 
transfected T98G cells (lane 2), in SV-myb T98G cells after methotrexate 
selection (SVmyb M T98G) (lane 3), and in the control MEL cells (lane 
4). (B) CD34 mRNA levels  were determined by RT-PCR in the presence 
(+) or absence (-) of reverse transcriptase. Each lane is representative of 
three independent experiments with similar results. (Lane 1) negative con- 
trol, HL-60 cells; (lane 2) T98G; cells, (lane 3) SV-myb T98G cells; (lane 
4) SV-myb T98G cells after methotrexate  selection; (lane 5) positive con- 
trol, KG-la cells (only one-fifth of the reaction was used); (lane 6) RT- 
PCR reaction  in the absence of RNA in the reaction mixture. 
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Figure 5.  Cell surface expression of CD34 in T98G constitutively ex- 
pressing c-myb. (A) KG-la cells: .... , negative control; -, anti-CD34.  (B) 
-, T98G; anti-CD34; - - -, SVmyb  T98G; anti-CD34, ...-, SVmybMT98G; 
anti-CD34, .-., negative control analysis, attached for the three cell lines, 
is reported, x-axis, number of cells; y-axis, fluorescence  intensity, log scale. 
The analysis was repeated twice  with identical results. 
of the c-rnyb transcription unit (Fig.  4 A, lane 3), but not 
in parental T98G cells (Fig. 4 A, lane 1). In SVmybM T98G 
cells, levels of c-myb protein expression were at least seven- 
fold greater than in SVmyb T98G cells, as revealed by den- 
sitometric scanning of the film (Fig.  4 A, compare lanes 3 
and 4). 
Expression of CD34 mRNA was not detected in control 
HL-60 cells (Fig.  4 B, lane I) or in nontransfected T98G 
cells (Fig. 4 B, lane 2), but was found in SVmyb T98G (Fig. 
4 B, lane 3),  and, at higher levels, in SVmybMT98G cells 
(Fig. 4 B, lane 4). Phenotypic analysis performed to monitor 
surface expression of the human CD34 antigen on T98G, 
SVmyb T98G and SVmybMT98G cells (Fig. 5 B) indicated 
expression  of CD34 antigen on a small proportion (4.3  +_ 
1.2%) of T98G cells. Low density CD34 expression was de- 
tected on SVmyb T98G cells, and most SVmybMT98G ex- 
pressed CD34 at a variable level, with average density ap- 
proximately half of that  detected in  KG-la  myeloblastic 
leukemia cells used as positive control (Fig.  5 A). 
Discussion 
The role of c-myb in hematopoiesis likely derives from its 
transactivating function, but the search for the relevant target(s) 
remains elusive, since two hematopoietic-associated targets, 
the MIM-1 and the lysozyme genes identified in avian cells, 
are expressed at a relatively late stage of myeloid differentia- 
tion. In contrast, expression of the CD34 stem cell marker 
declines during late stages of myeloid differentiation and matu- 
ration. Our data suggest that CD34 represents a primary target 
of c-myb regulation during the earliest recognizable  stages 
of hematopoietic progenitor cell commitment and differen- 
tiation. A temporal relationship in which c-myb expression 
precedes that of CD34 in human stem and progenitor cells 
is difficult to establish because primitive CD34-positive cells 
express c-myb, and CD34-negative stem cells, if they exist, 
cannot be identified yet. A functional and temporal relation- 
ship between c-myb and CD34 expression might be explored 
during the differentiation of embryonic stem cells. In these 
cells a stage can be identified at which c-myb, but not CD34, 
is expressed (26); this observation may support the involve- 
ment of c-myb in regulating CD34 expression during em- 
bryonal hematopoietic development. 
Our data clearly indicate that c-myb is a transcriptional 
factor involved in regulating CD34 expression,  but do not 
exclude that others are, too. Binding sites for ets proteins 
are present in the CD34 5' flanking region, some in close 
proximity with Myb binding sites, and preliminary findings 
suggest that c-myb and ets-2 act synergistically to transacti- 
vate the CD34 promoter. In addition, it is likely that c-myb 
expression is the only prerequisite for CD34 expression,  as 
implied by the lack of CD34 expression in the HL-60 cells 
promyelocytic leukemia cells that express c-myb  at high levels. 
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differentiation and express c-myb at high levels, and yet only 
KG-la cells express CD34. This suggests either positive regu- 
lation of CD34 expression by a c-myb partner in KG-la cells, 
or negative regulation in HL-60 cells by a suppressor of CD34 
expression. In this regard, a functional binding site for the 
myeloid-specific transactivator NF-M contiguous to a c-myb 
binding site appears to be necessary for c-myb regulation of 
the MIM-1 promoter (27); a similar mechanism may operate 
to control CD34 expression in early progenitor cells. Finally, 
the increased fraction of CD34-positive cells in acute leukemia 
patients correlates with the enhanced clonogenic potential 
of these cells and their high levels of c-myb expression. In 
conjunction with such observations, our data on c-myb regu- 
lation of CD34 expression might provide insights into the 
coupling of differentiation arrest and growth advantage in 
leukemic cells. 
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